Mangoceuticals leases Dallas office and separates from COO Hammer with severance

MANGOCEUTICALS, INC.

Enters 5-year lease for 2,467 sq ft Suite 245 at 17130 Dallas Parkway; base rent $4,852/mo + operating expenses.
COO Amanda Hammer terminated effective Oct 22, 2025; receives 9 months' salary in equal installments starting Nov 1, 2025.
Indigo Capital LP converts 500 Series B shares ($500,000 stated value) into 366,667 common shares at $1.50/sh conversion price.
Platinum Point Capital converts 32 Series B shares ($35,200 stated value) into 23,466 common shares on Oct 16, 2025.
Employment agreement with Hammer terminated; no material termination penalties incurred beyond severance.

item 1.01 item 1.02 item 2.03 item 3.02 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

MANGOCEUTICALS, INC. issued 23,466 shares of common stock of common stock to Platinum Point Capital, LLC for conversion of 32 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $35,200) pursuant to a conversion price of $1.50 per share.

Security: common stock
Shares: 23,466 shares of common stock
Purchaser: Platinum Point Capital, LLC
Consideration: conversion of 32 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $35,200) pursuant to a conversion price of $1.50 per share

Exact text from the filing

On October 16, 2025, Platinum Point Capital, LLC, a holder of the Company’s Series B Convertible Preferred Stock, converted 32 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $35,200) into 23,466 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $1.50 per share.

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

MANGOCEUTICALS, INC. issued 366,667 shares of common stock of common stock to Indigo Capital LP for conversion of 500 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $500,000) pursuant to a conversion price of $1.50 per share.

Security: common stock
Shares: 366,667 shares of common stock
Purchaser: Indigo Capital LP
Consideration: conversion of 500 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $500,000) pursuant to a conversion price of $1.50 per share

Exact text from the filing

On September 15, 2025, Indigo Capital LP, a holder of the Company’s Series B Convertible Preferred Stock, converted 500 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $500,000) into 366,667 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $1.50 per share.

View on SEC.gov

Browse all equity issuances →

MANGOCEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-25-019941

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.